Skip to main content
PLOS One logoLink to PLOS One
. 2026 Sep 25;21(9):e0358334. doi: 10.1371/journal.pone.0358334

Deep learning-based spatial immunoprofiling of multiplex immunofluorescence images distinguishes tuberculosis disease states in diversity outbred mice

Usama Sajjad 1,*, Nicholas A Crossland 2,3,4, Metin N Gurcan 5, Gillian Beamer 6, Muhammad Khalid Khan Niazi 1
Editor: Selvakumar Subbian7
PMCID: PMC13614646  PMID: 42789595

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), remains a major global health challenge, with approximately 10.8 million new cases and 1.25 million deaths reported in 2023. Human responses to M.tb are heterogeneous with clinical outcomes including bacterial clearance, asymptomatic latent M.tb infection, and severe fatal pulmonary TB. Here, we aim to address knowledge gaps in the organization of M.tb granulomas by identifying cell-based spatial features indicating asymptomatic lung infection. To address this gap, which cannot be directly studied in humans, we used lung sections from M.tb-infected Diversity Outbred mice with acute pulmonary TB, asymptomatic M.tb infection, or chronic pulmonary TB that were stained for T cells, B cells, macrophages, and bronchiolar epithelial cells by multiplexed immunofluorescence. We first developed a new, accurate model to automatically segment lung granulomas, detect/quantify the cell types within granulomas, and extract the location of immune cells in granulomas for each disease state. Analysis of model-derived results shows that lung granulomas from asymptomatic mice have a characteristic spatial profile consisting of higher CD4+ and CD8a+ T cell densities, closer B cell proximity to bronchiolar epithelium, and increased T cell-macrophage proximity in asymptomatic M.tb infection. Next, we propose a second novel approach to utilize a large language model (LLM) to independently decode complex cellular patterns within granulomas, and distinguish key immunological signatures: balanced immune expression in asymptomatic M.tb mice, dysfunctional responses with low cellularity in acute TB, and highest immune-cell abundance in chronic TB. Overall, the results from this study show that lung granulomas in asymptomatic infection are characterized by increased T cell density, increased numbers of peribronchiolar B cells, and T cells closer to macrophages as compared to acute and chronic TB. These methods and results help establish an automated pipeline to extract and analyze data from multiplexed fluorescence images and provide a foundation to better understand how granuloma architecture varies by disease state.

1. Introduction

Tuberculosis (TB), an infectious disease caused by the bacterial pathogen Mycobacterium tuberculosis (M.tb), remains a substantial global health threat. Epidemiological studies estimate that about one-quarter of the global population has been infected with M.tb [1]. In 2023, the global burden of TB reached 10.8 million new cases, an increase from 10.1 million cases in 2020 [1]. In adult humans, infection with M.tb results in a clinical spectrum including acute fulminant pulmonary TB with rapid progression to death within weeks; chronic pulmonary TB with slower lung-damaging progression often lasting years; and asymptomatic infection (e.g., incipient TB, latent M.tb infection (LTBI)); and clearance [2,3]. Symptoms of pulmonary TB are cough, fever, weight loss, and cachexia, due to tissue-destructive inflammation [4]. Notably, most humans with asymptomatic LTBI who progress to active pulmonary TB do so in the absence of identifiable risk factors [5], underscoring the multifactorial determinants of pulmonary TB progression, unpredictable nature of reactivation, and the need to improve our understanding of granulomas in different disease states, including asymptomatic LTBI.

M.tb infection initiates granuloma formation [6], which is the hallmark of infection that develops in response to molecular and cellular interactions between immune cells and bacterial components [7]. Granuloma formation is believed to begin with activation, recruitment and aggregation of leukocytes surrounding M.tb-infected macrophages, creating a protective barrier that limits bacterial dissemination [6], restricts M.tb replication and maintains LTBI. The spatial organization of immune cells within granulomas across different disease states, particularly the proximity of immune cells, macrophages, T cells, B cells, and bronchiolar epithelial cells and how these spatial relationships differ between asymptomatic LTBI, acute pulmonary TB, and chronic active TB are not fully known. Since controlled M.tb lung infection experiments cannot be directly performed in humans, we used lung sections from M.tb-infected DO mice. Each DO mouse represents a heterozygous mosaic of DNA inherited from eight founder strains [8,9], and when infected with M.tb, DO mice recapitulate human TB pathology more accurately than inbred strains of mice [10,11]. Here, we used multiplexed immunofluorescence imaging (mIF) of lung tissue sections from DO mice, to study and visualize the spatial location of CD19+ B cells, CD4+ helper T cells, CD8a+ cytotoxic T cells, EpCAM+ epithelial cells, and IBA1+ macrophages.

Given the structural complexity of granulomas, manual analysis cannot capture the spatially relevant relationships amongst immune cells and epithelial cells. The transition from traditional histopathology examination of glass slides to whole-slide imaging (WSI), combined with advances in high-speed data transfer and cost-effective storage, has enabled deep learning-based identification of complex histopathological patterns and feature quantification that is not possible by visual examination [12–18]. This advancement supported several new discoveries, including our prior work on imaging biomarkers in lung granulomas of M.tb-infected mice with and without BCG vaccination, and accurate prediction of gene expression based on granulomas [2,14,16,19].

Despite recent progress in applying deep learning to hematoxylin and eosin (H&E)–stained whole-slide images for tuberculosis phenotyping, these approaches remain biologically limited. H&E-based models primarily rely on global morphological pattern recognition, thereby obscuring cellular specificity and spatial immune interactions that are central to tuberculosis pathogenesis. Critical biological processes, including immune cell recruitment, compartmentalization, and cell–cell proximity within granulomas, cannot be resolved from H&E staining alone, as immune cell subtypes and functional states are visually indistinguishable. As a result, while H&E-based deep learning models can achieve disease-state classification, they provide less insight into the immune cell types that contribute to acute pulmonary TB, asymptomatic infection, and chronic pulmonary TB in DO mice. In contrast, mIF imaging enables simultaneous, cell-type–specific visualization of immune and epithelial populations and allows explicit quantification of spatial relationships within granulomas.

Previous studies in humans with pulmonary TB have shown that granuloma necrosis is at the center of granulomas, and is a distinguishing feature of DO mice with acute pulmonary TB [20–23], while an abundance of B-cells in perivascular and peribronchiolar cuffs identifies asymptomatic infection in DO mice [3]. The spatial relationship between immune cells and bronchiolar epithelial cells was a key motivation for using mIF imaging, yet manual quantification of these spatial patterns across entire lung sections was intractable. To address this limitation, we present an end-to-end framework that automates granuloma segmentation, classifies TB states more accurately than previous H&E-based methods, and quantifies spatial relationships between immune cell populations in granulomas. We replicate and validate the peribronchiolar B-cell signature of asymptomatic infection [3] using an independent method. By measuring the distance between CD19+ B-cells and bronchiolar epithelial cells in mIF images, we show that asymptomatic mice exhibit significantly closer B-cell-epithelial cell proximity than DO mice with acute pulmonary TB (“progressors” that survive less than 60 days) or chronic pulmonary TB (“controllers” that survive greater than 60 days), independently confirming previous findings [3] using automated spatial analysis. Finally, we integrate large language models to interpret complex cellular patterns by synthesizing cell identities, spatial coordinates, expression intensities, and attention-derived importance scores, extracting biologically interpretable insights that distinguish TB disease states. This approach also addresses the limitations of traditional hypothesis-driven methods, which, while valuable, can be constrained by fixed assumptions and human bias, potentially overlooking the complex, multi-dimensional biological patterns that emerge from integrating multi-modal data. By identifying relationships across these diverse data modalities without predetermined hypotheses, LLMs enable discovery of novel biological insights that may be difficult to capture through conventional statistical methods alone. Overall, this study integrates mIF imaging, attention-based MIL, and LLM-driven interpretation to characterize granuloma-level cellular and spatial patterns associated with distinct TB disease states in a genetically diverse animal model.

2. Materials and methods

2.1. Ethics statement

All lung tissue sections analyzed in this study were archived specimens generated from previously conducted M.tb infection experiments at Tufts University. These experiments were performed under protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Tufts University (protocol numbers: G2012-53, G2015-33, G2018-33, and G2020-121). Experimental procedures involving M.tb were approved by the Institutional Biosafety Committee (IBC) at Tufts University under registration numbers GRIA04, GRIA10, GRIA17, and 2020-G61. No new animal experiments were performed specifically for the present study. All animal handling and experimental procedures adhered to institutional guidelines for the ethical treatment of laboratory animals.

2.2. Experimental animals and tissue samples

Our dataset comprises 48 mIF lung tissue sections, a small, curated subsample of preserved and processed lung tissue samples archived in paraffin blocks from our previous studies and obtained from 48 individual M.tb mice [3,22,24,25]. The experimentally infected DO mice represent three distinct disease states: Progressors (n = 15), Asymptomatic (n = 17), and Controllers (n = 16). Samples for mIF analysis were retrospectively selected from the archived cohorts to capture the full range of bacterial burden and survival outcomes within each disease class while maintaining relatively balanced group sizes for downstream analysis. These mice were infected with M. tb Erdman strain by aerosol with a retained lung dose of 25–100 colony forming units (CFU) [24]. Tissue sections were collected at the time of euthanasia, which varied by disease outcome: Progressors were euthanized between 22 and 51 days post-infection (μ = 27.05 days) of infection reflecting acute pulmonary TB, Controllers were euthanized between 114 and 418 days post-infection (μ = 255 days) reflecting chronic pulmonary TB, and Asymptomatic mice showed no clinical signs of disease throughout the observation period and were euthanized between 48 and 50 days post-infection (μ = 49 days). These disease classifications were determined based on clinical and histopathological criteria as described in previous studies [3,25].

Predetermined humane endpoints for euthanasia were severe weakness or lethargy, respiratory distress, or a body condition score below 2 [3,24]. The lung sections in this dataset were from 48 mice euthanized by CO2 asphyxiation followed by vital organ removal in accordance with AVMA with the duration of M.tb infection corresponding to 418 days for the longest surviving Controller. Animal health and behavior were monitored daily for routine observations and body weights taken at least once per week with increased frequency instituted if consecutive weight loss was detected. Standard animal care and housing included ventilated HEPA-filtered racks, controlled light:dark cycles (12:12 hours), sterile corncob bedding, sterile paper nestlets, and enrichment, cage changes at least every other week, and sterile food and acidified water provided ad libitum. Tufts University Institutional Animal Care and Use Committee reviewed and approved all procedures on live animals under protocols G2012-53, G2015-33, G2018-33, and G2020-121, and the committee required predetermined euthanasia criteria as listed above. Biosafety Level 2 and Biosafety Level 3 practices were approved by Tufts University’s Institutional Biosafety Committee. Post-infection euthanasia timing and lung bacterial burden across the three disease states are summarized in Table 1.

Table 1. Summary of post-infection euthanasia day and lung M.tb bacterial burden across disease states. Euthanasia day and lung CFU ranges are shown for Progressors (n = 15), Asymptomatic (n = 17), and Controllers (n = 16). Values represent the range and mean (μ) for each group. Bacterial burden is reported as CFU per lung. Progressors were euthanized within 60 days of infection reflecting acute pulmonary TB; Asymptomatic mice showed no clinical signs of disease; and Controllers were euthanized after 60 days reflecting chronic pulmonary TB.

Disease states Post-infection euthanasia day Bacterial burden (CFU)
Progressor 22–51 (μ = 27.05) 5,855,856–450,450,450 (μ = 270,132,856.4)
Asymptomatic 48–50 (μ = 49) 42,793–380,630,631 (μ = 24,219,541.71)
Controller 114–418 (μ = 255) 1,576,577–12,612,612,613 (μ = 1,072,447,056.5)

2.3. Staining protocol

Tissue sections were stained using a tyramide signal amplification (TSA)-based protocol. In each staining cycle, a primary-secondary antibody complex was applied, followed by covalent deposition of the fluorophore onto the tissue via tyramide signal amplification. The primary-secondary antibody complex was then stripped iteratively using heat and a low-pH citrate buffer, while the covalently bound fluorophore signal was retained in the tissue. This cycle was repeated sequentially for each target marker (CD4+, CD8a+, CD19+, EpCAM+, and IBA1+) on the same tissue section, enabling simultaneous visualization of all five immune and epithelial cell populations without cross-reactivity between staining rounds.

2.4. Computational framework for granuloma segmentation, disease-state classification, and spatial interpretation

Previous studies have established that granuloma necrosis is at the center of granulomas, and a distinguishing feature of super susceptible progressor DO mice [20–23], while B-cells in perivascular and peribronchiolar cuffs identify asymptomatic latent infection [3]. The spatial relationship between B-cells and bronchiolar epithelial cells was a key motivation for developing mIF imaging, yet manual quantification of these spatial patterns across entire lung sections remains intractable. To address this limitation, we present an end-to-end framework that automates granuloma segmentation, classifies disease states with substantial improvements over H&E-based methods, and quantifies spatial relationships between immune cell populations at the granuloma level. In this section, we discuss the methodology of our framework in detail. Our dataset consists of entire lung sections, requiring an initial step to segment the TB granulomas. From the segmented images, we then train a deep learning model to predict disease state. Finally, we use an LLM to interpret the spatial patterns of immune cells within high-attention regions identified by our classification model, extracting biologically meaningful insights that distinguish the three disease states. The entire workflow of our framework is presented in Fig 1.

Fig 1. An overview of our proposed framework.

Fig 1

A. mIF images are processed using the IF-UNet++ model to segment granulomas. The resulting segmentation outputs are divided into patches for further analysis. B. These patches are fed into a MIL model to predict disease-state classification. A trained MIL model, along with an LLM, integrates MIL-derived features and immune cell spatial patterns to infer immune cell patterns.

2.4.1. Segmentation of granulomas from lung tissue sections.

The objective of the segmentation component is to accurately delineate tuberculosis granulomas from multiplex immunofluorescence whole-slide images, thereby defining biologically meaningful regions for downstream spatial and disease-state analysis. Each lung section contains complex and heterogeneous tissue architecture, necessitating an automated approach capable of capturing granuloma boundaries across diverse immune phenotypes. To this end, we employ an immunofluorescence-adapted UNet++ architecture (IF-UNet++), which leverages multiscale feature aggregation and dense skip connections to preserve fine-grained cellular and structural information across multiple immunofluorescence channels.

To study the granulomas, we first identify granulomas from mouse lung WSIs. Given N WSIs, we extract M non-overlapping patches, where M may vary per WSI depending on its size. Each input patch xi ∈ R H × W × D comprises H × W pixels across D immunofluorescence channels, with each channel corresponding to a distinct cellular marker. The corresponding ground truth segmentation mask yi ∈ {0,1}H × W represents a binary mask delineating the granuloma boundary. This yields a dataset 𝒟 comprising paired patches (xi) and its ground truth (yi). Our objective is to learn a mapping function f: x → y that accurately predicts the segmentation mask yi for each input patch xi.

We propose an IF-UNet++ architecture [26] optimized for immunofluorescence image segmentation to learn this mapping function f. Unlike cell segmentation tools such as Cellpose [27] designed to delineate individual cell boundaries, IF-UNet++ is optimized to identify granuloma-level boundaries, treating each granuloma as a single multicellular functional unit, which is necessary for all downstream spatial analyses. Our architecture employs a nested encoder-decoder structure interconnected through dense skip pathways [26]. The encoder performs progressive downsampling while computing hierarchical feature representations at multiple spatial resolutions. Unlike the standard U-Net, which directly concatenates encoder features with decoder features at matching resolutions, IF-UNet++ introduces intermediate convolution blocks along each skip pathway. These blocks iteratively refine encoder representations before fusion with decoder outputs. At each computational node, we aggregate features from all preceding nodes along the pathway and upsample features from deeper layers through a series of convolution operations, enabling dense information flow across network hierarchies.

We train our network with deep supervision, attaching segmentation heads at multiple semantic levels. The loss function combines binary cross-entropy and Dice coefficient, enabling the model to learn representations at different scales simultaneously. During inference, the final segmentation mask is generated by averaging outputs from all segmentation branches, producing pixel-wise predictions that identify granuloma regions within each patch. The overall loss function for the segmentation model is defined as (Eq. 1):

Lg=−1N′ (∑b=1B12YblogYb^+ 2. Yb.Yb^Yb+Yb^) (1)

where B represents the batch size, Yb denotes the flattened ground truth segmentation mask for the bth image, and Yb^ represents the flattened predicted probability map. This formulation combines two complementary objectives to optimize segmentation performance. The first term represents binary cross-entropy, which measures pixel-wise classification error and encourages accurate probability estimates at each pixel location. The second term corresponds to the Dice coefficient, which quantifies overlap between predicted and ground truth masks. The negative sign converts this into a minimization problem. By minimizing Lg during training, the network learns to generate accurate pixel-wise predictions that effectively segment granulomas from lung tissue sections.

During WSI-level inference, we partition incoming WSI into non-overlapping patches, process each patch independently using f, and reconstruct the full segmentation map by spatially stitching the predicted outputs to generate a complete WSI-level segmentation.

2.4.2 Multiple instance learning for disease state classification.

Whole-slide lung sections from M. tuberculosis–infected mice exhibit substantial intra-slide heterogeneity, with multiple granulomas and surrounding tissue regions contributing differently to disease phenotype. Assigning patch-level disease labels is therefore biologically ill-defined, as disease state emerges from the collective behavior of multiple granulomas rather than from any single localized region. Multiple instance learning (MIL) provides a principled framework for this setting by enabling slide-level classification while allowing the model to learn which granuloma regions are most informative for disease discrimination [28–30]. Importantly, attention-based MIL further permits identification of high-impact regions, offering a direct link between model predictions and biologically meaningful tissue compartments.

In this section, we describe the Multiple Instance Learning (MIL) model [31] used to classify lung tissue sections from M.tb-infected DO mice into three distinct disease states: asymptomatic infection, acute pulmonary tuberculosis in progressors, and chronic pulmonary tuberculosis in controllers.

Our training set consists of N gigapixel-scale WSIs, where each WSI (Xi) represents a DO mouse lung tissue section containing one or more granulomas. These WSIs are denoted as bags:

X={X1, X2, …, XN}

with corresponding disease-state labels

Y={Y1, Y2, …, YN}

where Yl ∈ {0, 1, 2} for l∈{1,…,  N}, corresponds respectively to asymptomatic, acute, and chronic TB states.

Under the MIL formulation, each WSI is decomposed into a set of non-overlapping image patches (instances),

Xi= {xi1, xi2, …, xinj}

where nj denotes the total number of patches extracted from the ith WSI, and j=1,…,nj indexes the patches within the ith WSI. Each patch xij∈R H × W × C corresponds to a H × W region with C immunofluorescence channels, and each channel contains a cellular marker (e.g., CD4⁺, CD8a⁺, CD19⁺, EpCAM⁺, IBA1⁺), capturing the spatial and phenotypic diversity of immune microenvironments.

Since patch-level labels {yij} are unknown during the training process, the model operates under weak supervision, where only bag-level disease states Yi are known. This formulation allows the network to learn discriminative representations by inferring which patches contribute most to the disease state label, despite substantial intra-bag heterogeneity across granulomas. Therefore, we adopt an attention-based Multiple Instance Learning (ABMIL) architecture to perform multi-class disease state classification. The model comprises three primary components: a patch encoder, an attention-based aggregator, and a classifier.

The patch encoder component fp(.;θf) maps each patch xij into a high-dimensional embedding D:

 hij= fp(xij;θf)∈R D

using a convolutional neural network (CNN) backbone trained to capture local morphological and cellular spatial features within each patch.

To aggregate patch embeddings into a single bag-level representation, we employ a gated attention mechanism that computes a weighted average over patch features:

zi= σ(hi1, hi2, …, hini)= ∑j=1niaijhij

where aij denotes the normalized attention weight for the jth patch. The weights form a probability distribution over all patches:

aij= exp(wij)∑k=1niexp(wik))

with the unnormalized attention logit defined as:

wij= WT(tanh(VThij) ∎sigm(UThij) )

Here, V, U ∈R D × L are learned projection matrices, W∈ R L × 1 is a learned vector, tanh, sigm denote hyperbolic tangent and sigmoid activations respectively, and ∎ represents element-wise multiplication. This gated attention mechanism allows the network to model complex, nonlinear dependencies between patches and their relevance, effectively emphasizing granuloma regions that are most informative for disease state discrimination.

The resulting aggregated embedding zi ∈R D serves as a compact, disease-state-specific representation of the WSI, summarizing key morphological and immunological cues across all patches. Then, a fully connected layer with a SoftMax activation outputs a categorical probability distribution over the three disease states. The model is trained using categorical cross-entropy loss. We minimize this loss to enable the network to learn discriminative, attention-weighted feature representations that accurately capture the morphological and immunological signatures associated with distinct TB disease states.

2.4.3. Large language model-based interpretation of spatial patterns.

The intricate spatial organization of immune cells within granulomas requires simultaneous integration of cell types, spatial distributions, expression intensities, and their interdependencies across disease states, demanding consideration of countless feature combinations across hundreds of tissue patches. To address this complexity, we employed a large language model (LLM) [32] to decode complex spatial patterns within high-attention regions of TB granulomas and identify recurring patterns across disease states (Fig 7).

Fig 7. Framework for TB disease state classification and interpretation.

Fig 7

(A) mIF imaging workflow from lung tissue to WSI generation. (B) Deep learning pipeline integrating cell type identification, spatial analysis, and LLM-based decoding to interpret disease-specific patterns. (C) Disease state characterizations: Progressor (low cellularity, weak immune response), Asymptomatic (balanced immune control), and Controller (high cellularity, strong inflammatory response).

We provided the model with comprehensive quantitative information for each granuloma patch, including: (1) predicted disease state (asymptomatic, chronic pulmonary TB, acute pulmonary TB), (2) cell types (CD19+, CD4+, CD8a+, EpCAM+, IBA1+), (3) spatial location of cells, (4) expression intensity values for each cell, (5) patch-level attention scores derived from the ABMIL model indicating discriminative capability, and (6) spatial coordinates defining patch positions within the granuloma structure. We tasked the model with identifying distinct cellular and spatial patterns that differentiate the three disease groups.

2.4.4. Implementation details.

For training the IF-UNet++ segmentation model, we employed five-fold cross-validation to ensure robust performance evaluation and model selection, using a batch size of 16 and a learning rate of 1 × 10−3. In each fold, 80% of the data was used for training, with 10% randomly selected from the training set for validation and the remaining 20% held out for testing. We monitored validation performance across all folds and selected the model with the best validation loss for granuloma segmentation for subsequent disease state classification, ensuring that the segmentation model generalized well to unseen data before being integrated into the downstream classification pipeline. For the ABMIL model, we employed five-fold cross-validation (70%/10%/20%) split with a learning rate of 1 × 10−4, and a batch size of 1.

3. Results

The overall goal of this study is to develop an end-to-end framework capable of segmenting granulomas from lung tissue sections, classifying TB disease states, utilizing LLMs for identifying cellular patterns, and spatial quantification of cellular composition in M.tb-infected DO mice. In this section, we present the performance of IF-UNet++, disease state classification, and an interpretation of cellular patterns using an LLM.

3.1. Granuloma segmentation using IF-UNet++

Accurate delineation of granulomas is critical for extracting informative features and training reliable disease state classification models. Granuloma boundary annotations were delineated by a board-certified pathologist, providing biologically accurate and consistent ground truth segmentation masks for model training. Notably, deep learning segmentation models learn by identifying recurring patterns in training data; inconsistent or contradictory annotations would prevent the model from learning a coherent decision boundary, resulting in poor generalization. Our segmentation network, IF-UNet++, effectively segmented granulomas, achieving an Intersection over Union (IoU) of 93.22% on the training set and 90.57% on the independent test set. The IoU metric serves as a comprehensive surrogate for granuloma morphological accuracy, implicitly encoding agreement in size, shape, spatial extent, and boundary fidelity within a single unified measure. The high IoU of 90.57% achieved on the held-out partitions within five-fold cross validation therefore serves not only as a measure of model accuracy, but also as indirect quantitative evidence that the underlying annotations were consistent and reproducible across the dataset. Beyond quantitative evaluation, segmentation results were mapped back to the original mIF images and qualitatively reviewed by a board-certified pathologist, who confirmed that the predicted granuloma boundaries were spatially concordant with true granulomatous structures across all disease phenotypes. These results highlight its strong generalization ability and robust segmentation performance. Representative examples of the segmentation output are shown in Fig 2. Panels A, B, and C illustrate automated granuloma segmentation across the three disease states: Progressor (survive < 60 days); asymptomatic infection, and controller (survive greater than 60 days) [3], with predicted granuloma boundaries outlined in yellow. The segmentation outputs exhibit high spatial concordance with granulomatous structures across all disease phenotypes, underscoring the model’s ability to accurately capture granulomas within complex pulmonary microenvironments. Panel D presents the confusion matrix demonstrating our framework’s classification performance, achieving high accuracy in distinguishing between the three TB disease states with minimal misclassification.

Fig 2. IF-UNet++ granuloma segmentation across disease states and classification performance.

Fig 2

Representative examples of automated granuloma segmentation in lung tissue sections from DO mice across three disease states: (A) Progressor (acute pulmonary TB), (B) Asymptomatic (latent infection), and (C) Controller (chronic pulmonary TB). Each panel shows the original mIF image with predicted granuloma boundaries outlined in yellow. (D) Confusion matrix showing the classification performance of our framework in distinguishing between the three disease states.

3.2. Granuloma-level analysis of immune cell populations

Statistical comparisons of immune cell abundance across disease states were performed using nonparametric tests because cell counts were non-normally distributed across granulomas. Group-wise differences were assessed followed by post hoc pairwise comparisons with appropriate multiple-testing correction. These analyses confirm that observed differences in immune cell composition across Progressor, Asymptomatic, and Controller groups reflect systematic biological variation rather than sampling variability.

To characterize the cellular heterogeneity underlying different TB disease states, we quantified the distribution of immune cell populations within each granuloma across the three disease groups (Fig 3, Supplementary Figure S1 (S1 File)). CD4+ T helper cells demonstrated a progressive increase in Asymptomatic in comparison with Progressor and with intermediate levels observed in Controllers (Fig 3A). CD8a+ cytotoxic T cells were most abundant in the Asymptomatic group compared to both the Progressor and Controller groups (Fig 3B). CD19+ B cells showed relatively sparse distribution across all disease states, with slightly elevated levels in Controllers (Fig 3C). EpCAM+ epithelial cell abundance was comparable across groups, suggesting similar cellular composition (Fig 3D). These cells were confirmed to be bronchiolar epithelial cells based on the anatomic structure highlighted by board-certified pathologists. Notably, IBA1+ macrophages exhibited substantially higher macrophage density in Asymptomatic mice compared to both Progressor and Controller groups. When examining total cell abundance (Fig 4, Supplementary Figure S2 (S1 File)), Controller granulomas consistently exhibited the highest absolute cell counts across all immune cell types, including CD4+ T cells, CD8a+ T cells, CD19+ B cells, EpCAM+ epithelial cells, and IBA1+ macrophages. Total immune-cell abundance across the three disease states is shown in Fig 4 and Supplementary Figure S2 (S1 File).

Fig 3. Density of immune cell populations per unit granuloma area across TB disease states.

Fig 3

Box plots show density of cells, reported as density per unit granuloma area for (A) CD4+ T cells, (B) CD8a+ T cells, (C) CD19+ B cells, (D) IBA1+ macrophages, and (E) EpCAM+ epithelial cells across three disease groups: Progressor, Asymptomatic, and Controller. Each dot represents one granuloma; box plots show median, interquartile range, and whiskers extending to 1.5 × IQR.

Fig 4. Total numbers of immune cells in granulomas across TB disease states.

Fig 4

Box plots showing cell abundance for (A) CD4+ T cells, (B) CD8a+ T cells, (C) CD19+ B cells, (D) IBA1+ macrophages, and (E) EpCAM+ epithelial cells across three disease groups: Progressor, Asymptomatic TB, and Controller, (F) Total number of immune cells per lung tissue section. Each dot (4A-4E) represents one granuloma; box plots show median, interquartile range, and whiskers extending to 1.5 × IQR.

3.3. Deep learning accurately predicts disease states from granulomas

To differentiate between DO mice with asymptomatic M.tb infection, from progressors with acute pulmonary TB, and controllers with chronic pulmonary TB, we trained and evaluated our model on segmented granuloma regions. Our mIF-based classification model achieved an AUC of 0.982, with 90.0% accuracy, 91.1% sensitivity, and 95.1% specificity. In comparison, our previous H&E-based approach attained an AUC of 0.884, sensitivity of 71.9%, and specificity of 89.9% (Table 2). For multi-class evaluation, the reported AUC corresponds to a macro-averaged one-vs-rest formulation across the three disease states. These results demonstrate substantial performance improvements, particularly in sensitivity, highlighting the value of cell-type-specific spatial information provided by mIF imaging for disease state classification.

Table 2. Performance comparison of disease state classification methods. Our model was evaluated using five-fold cross-validation to classify lung tissue sections into three disease states: asymptomatic infection, acute pulmonary TB, and chronic pulmonary TB. Values in parentheses represent 95% confidence intervals.

Method AUC Accuracy Sensitivity Specificity
Koyuncu et al. [3] 0.884
(0.862 - 0.903)
– 71.90%
(63.2 - 80.4)
89.90%
(87.3 - 92.1)
Ours 0.982
(0.953 - 1.00)
90.00%
(81.0–98.94)
91.11%
(82.9–99.23)
95.08%
(90.64 - 99.52)

3.4. B-cells in asymptomatic infection near bronchiolar epithelial cells

To validate the peribronchiolar B-cell signature identified in a previous study [3] and demonstrate the practical utility of our framework for spatial analysis, we quantified the distance between CD19+ B-cells and bronchiolar epithelial cells across disease states (Fig 5). Figure 5A presents a polar coordinate visualization of a representative granuloma from each disease state, illustrating the spatial distribution of immune cells as a function of distance from the center of the granuloma. Figure 5B shows that Asymptomatic mice exhibit shorter distances between each bronchiolar epithelial cell and its nearest B-cell compared to both Progressors and Controllers, indicating closer spatial association and independently confirming the peribronchiolar B-cell signature [3] using mIF imaging and automated spatial analysis, validating previous observations through a complementary methodology.

Fig 5. Spatial organization of B-cells in granulomas from M.tb-infected DO mice.

Fig 5

(A) Polar plot of a representative granuloma showing spatial distribution of cells (Progressor: red, Asymptomatic: blue, Controller: green). Concentric circles indicate normalized radial distance from granuloma centroid. Each point represents the distance between each bronchiolar epithelial cell with the nearest CD19+ B cell. (B) Mean distance between bronchiolar epithelial cells and nearest CD19+ B cell. Each point represents one mouse (averaged across all granulomas), demonstrating closest proximity in Asymptomatic.

3.5. Spatial relationships between T cells and macrophages reveal disease-specific immune organization

To further characterize the spatial immune architecture within TB granulomas, we quantified the proximity between T cell populations (CD4+ and CD8a+) and IBA1+ macrophages across the three disease states (Fig 6). Figures 6A and 6B present the mean distances between CD4+ T cells and nearest macrophages, and CD8a+ T cells and nearest macrophages, respectively, across Asymptomatic, Controller, and Progressor groups. To assess whether T cells were positioned within functional proximity to macrophages, we defined a threshold of 75 μm radius as the spatial range for potential T cell-macrophage interactions based on [33]; this radius was converted to 150 pixels (75 μm / 0.5 = 150 px) using the spatial resolution of 0.5 mpp of our WSIs. While both CD4+ and CD8a+ T cells showed variable distances to macrophages across individual mice, the overall proximity patterns differed among disease states with the smallest mean distance between T cells and macrophages in asymptomatic mice in comparison with other groups. Figure 6C presents a two-dimensional visualization comparing the proportion of CD4+ cells within 75 μm of macrophages versus the proportion of CD8a+ cells within 75 μm of macrophages for each mouse. This analysis revealed distinct clustering patterns: Asymptomatic mice exhibited higher proportions of both T cell subsets in close proximity to macrophages, suggesting coordinated immune cell positioning that may facilitate effective pathogen control. Controllers displayed intermediate spatial patterns, while Progressors showed more dispersed and variable T cell-macrophage relationships, potentially reflecting impaired immune coordination. Figure 6D quantifies these observations, showing that Asymptomatic maintains the highest proportion of both CD4+ and CD8a+ T cells within 75 μm of macrophages, followed by Progressors with preferential CD4+ proximity and reduced CD8a+ proximity, and Controllers showing balanced but reduced overall T cell-macrophage proximity compared to Asymptomatic. These spatial profiling results demonstrate that the physical organization of T cells relative to macrophages differs systematically across TB disease states, with closer T cell-macrophage proximity in Asymptomatic potentially reflecting more effective immune surveillance and pathogen containment within granulomas.

Fig 6. Spatial profiling of T cell-macrophage proximity in TB granulomas.

Fig 6

(A) Swarm plot presenting a mean distance between CD4+ T cells and nearest IBA1 + macrophage per mouse. Each point represents one mouse (averaged across all granulomas); red dashed lines indicate mean values. (B) Swarm plot presenting mean distance between CD8a+ T cells and nearest IBA1+ macrophage. (C) Scatter plot showing joint T-cell proximity to macrophages. Each point represents one mouse, with x-axis showing the proportion of CD4+ T cells within 75 μm of macrophages and y-axis showing the proportion of CD8a+ T cells within 75 μm of macrophages. (D) Bar plot comparing the proportion of CD4+ and CD8a+ T cells within 75 μm radius of each macrophage across the three disease states, demonstrating differential spatial organization patterns characteristic of each TB disease phenotype.

3.6. Interpreting Disease-specific spatial patterns using large language models

Multi-modal large language models have demonstrated promising capabilities for analyzing histopathology images [34-36]. Recent approaches [34,35] enable automated quantification and interpretation of morphological markers in large data cohorts, addressing key limitations of manual quantification, which is time-consuming and subject to interobserver variability. Here, we leverage an LLM [32,37] as an integrative reasoning engine to synthesize multi-modal computational outputs (cell identities, spatial coordinates, expression intensities, and attention scores) into interpretable biological narratives, enabling an automated hypothesis-free pattern discovery across complex spatial immune phenotypes. Using this approach, LLMs [32,38,39] serve as a higher-level interpretive layer that summarizes recurring, disease-specific immune architectures across high-impact granuloma regions. The LLM-based spatial interpretation framework is illustrated in Fig 7. We tasked the model with identifying distinct cellular and spatial patterns that differentiate the three disease groups.

The following are the findings of the LLM:

  1. Progressors are characterized by relatively low overall cellularity and dysfunctional expression of immune cells. While CD4+ T cells are numerically present, their expression is notably low.

  2. Asymptomatic mice display a balanced cellular landscape with moderate overall cellularity and expression. A well-coordinated expression of macrophages, CD4+ and CD8a+ T cells, and epithelial cells. This immune response indicates effective pathogen containment without inducing excessive inflammation or tissue damage, representing an optimal host-pathogen equilibrium.

  3. Controllers exhibit the highest overall cellularity and widespread, intense immune expression level across all cell types. High expression of CD4+ and CD8a+ T cells, B cells, and macrophages signifies a robust, hyper-inflammatory response. This aggressive, broad-spectrum immune mobilization effectively contains the pathogen but likely contributes to significant immunopathology due to excessive inflammation and tissue damage.

Importantly, these interpretations were derived from model-generated quantitative inputs rather than raw image data. The identified patterns were concordant with independently quantified differences in cellular abundance and spatial proximity, supporting their biological plausibility.

3.7. Spatial organization of immune and epithelial cell populations in relation to lung M.tb burden across disease states

To examine whether the spatial organization of immune cells is associated with lung bacterial burden, we computed Spearman correlation coefficients between the log-transformed mean distance of each immune cell with its nearest immune cell and M.tb CFU per lung, stratified by disease group (Fig 8). The results reveal that spatial-bacterial relationships are disease-state-specific rather than uniform across groups. Asymptomatic mice exhibited the most consistent associations between T cell spatial positioning and bacterial burden, suggesting that T cell proximity within granulomas is meaningfully coupled to bacterial containment in this group. In contrast, Progressors and Controllers showed more variable spatial-bacterial relationships across immune populations, respectively.

Fig 8. Correlation between spatial distribution of immune cells and M.tb burden across disease states.

Fig 8

(A). Log mean distance for CD4+ T cells (B). CD8a+ T cells, (C). CD19+ B cells, (D). IBA1+ macrophages, and (E). EPCAM+ epithelial cells plotted against M.tb burden for each mouse. Each point represents one mouse, colored by disease group: Asymptomatic (blue), Controllers (green), and Progressors (red). Per-group Spearman correlation coefficients (ρ) and associated p-values are shown in each panel legend.

4. Discussion and conclusions

This study presents an end-to-end framework for automated analysis of lung granulomas from M.tb-infected DO mice using mIF images stained for CD4 and CD8a T cell subsets, B cells, macrophages, and bronchiolar epithelial cells. Our framework involves automated granuloma segmentation, disease-state classification, and interpretability analysis to decode the organization of immune cells within TB granulomas, addressing fundamental limitations of manual annotation and traditional H&E-based computational approaches.

Our proposed IF-UNet++ segmentation model achieved robust performance in delineating granulomatous regions, with an IoU of 93.22% on the training set and 90.57% on the independent test set. These results demonstrate strong generalization and establish accurate spatial boundaries, which are essential for downstream feature extraction and disease-state classification (Fig 2). Based on the segmentation outputs, granulomas in Asymptomatic mice may appear morphologically similar in size and shape to those in Progressors on mIF imaging, but the key distinguishing pathological feature of Progressor granulomas is neutrophilic infiltration and necrosis, which is not visible by mIF imaging but is clearly demonstrable by H&E staining, as we have described previously [2,3,14,22,24,25]. Building on these segmentation outputs, our attention-based multiple instance learning (ABMIL) framework achieved substantial improvements in disease-state classification over previous approaches. Compared to our previous H&E-based method, the mIF-based model demonstrated an 11.1% increase in AUC (0.982 vs. 0.884), a 26.7% increase in sensitivity (91.1% vs. 71.9%), and a 5.8% increase in specificity (95.1% vs. 89.9%). These marked performance gains, particularly the substantial enhancement in sensitivity, highlight the value of cell-type-specific spatial information provided by mIF images.

Our spatial and cellular analyses revealed distinct patterns that differentiate TB disease states in DO mice at the granuloma level. When examining density per granuloma area (Fig 3), we observed that CD4+ T cells and CD8a+ T cells were most abundant in Asymptomatic, suggesting a balanced adaptive immune response associated with effective pathogen control. In contrast, IBA1+ macrophages showed substantially higher density in Asymptomatic mice compared to both the Progressor and Controller groups, indicating a well-regulated innate immune response. Analysis of total cell counts (Fig 4) revealed that Controller granulomas consistently exhibited the highest absolute cell numbers across all immune cell types. Critically, our analysis also validated that the peribronchiolar B-cell signature identified in our previous studies [3], where asymptomatic mice demonstrated significantly closer proximity between CD19+ B-cells and bronchiolar epithelial cells compared to Progressor and Controller groups (Fig 5). This independent confirmation through mIF imaging and automated spatial quantification not only validates prior findings but also demonstrates the translational utility of our framework for discovering and validating spatial biomarkers that are associated with protective immunity versus disease progression. These cell-type-specific spatial patterns may provide mechanistic insights into the differential immune responses underlying asymptomatic infection, acute pulmonary TB, and chronic pulmonary TB.

Granuloma organization, the cell types within the granulomas, and the function of immune cells within granulomas and their subregions are important to understanding clinical cases of pulmonary TB in humans and in animal models of M.tb infection [40–44]. However, few studies compare immune cell types across different disease states. Here, our spatial profiling analysis quantifies density per unit area of granuloma, total count per lung tissue section, and distances of immune cells in lung granulomas from DO mice with acute pulmonary TB, asymptomatic infection, and chronic pulmonary TB. Our work reveals that T cell-macrophage proximity patterns are disease-state specific and may serve as functional indicators of immune coordination. Our findings indicate that asymptomatic mice maintain the closest spatial relationships between both CD4+ and CD8a+ T cells and IBA1+ macrophages, with the highest proportions of both T cell subsets positioned within the 75 μm range. This spatial organization may facilitate effective and coordinated pathogen containment mechanisms critical for maintaining control of asymptomatic latent infection. In contrast, progressors exhibited more dispersed and variable T cell-macrophage spatial relationships, potentially reflecting breakdown of organized immune architecture and impaired cell-cell communication necessary for granuloma function. Controllers displayed intermediate patterns, suggesting partially maintained but suboptimal immune coordination. These findings extend beyond simple cell abundance metrics to reveal that the physical organization of immune cells within granulomas is a critical determinant of disease outcome, highlighting the importance of spatial profiling approaches for understanding TB pathogenesis and identifying potential therapeutic targets aimed at restoring functional immune architecture.

Another novel contribution of this work is the integration of LLMs to interpret complex immune organization within TB granulomas. We provided the LLM with comprehensive multi-modal data, including predicted disease states, cell identities, spatial coordinates, protein expression intensities, and patch-level attention scores derived from the model. Through this integrative analysis, the LLM identified disease-specific spatial patterns that were independently validated by our quantitative analyses. For example, the LLM identified coordinated spatial clustering of macrophages, CD4+ T cells, and CD8+ T cells in asymptomatic mice, which was corroborated by the spatial relationship analyses shown in Figs 6A and 6B. Similarly, the LLM’s identification of elevated overall cellularity in controllers was validated by the quantitative measurements presented in Fig 4. These findings provide an automated, scalable framework for discovering distinctive spatial immune patterns within granulomas without requiring pre-defined hypotheses or manual feature selection.

The translational impact of this work is fundamentally enabled by our use of the DO mouse population, which directly addresses a critical barrier in TB research: the failure of traditional inbred mouse models to recapitulate the heterogeneity of human disease. Unlike inbred strains, DO mice capture the broad spectrum of clinical outcomes seen in human populations from LTBI to progressive pulmonary disease, thereby providing an unprecedented animal model for training computational models on biologically realistic disease variability. This genetic diversity not only strengthens the translational relevance of our findings but also enables our framework to learn from granuloma phenotypes that mirror the complex host-pathogen interactions underlying human TB pathogenesis, making our identified spatial biomarkers directly relevant to human disease heterogeneity.

Beyond its application to murine models, the proposed framework is directly extensible to emerging human spatial immunology datasets, including multiplex immunofluorescence and spatial transcriptomics of lung tissue. By explicitly modeling cell-type–specific spatial relationships within granulomas, this approach provides a scalable pathway for translating insights from genetically diverse animal models to human tuberculosis, where similar immune architectures underlie heterogeneous clinical outcomes.

Despite several breakthroughs in this study, there are several limitations. First, our dataset included only 48 mIF-stained lung tissue sections. Although this dataset provided a strong foundation, expanding to larger, multi-institutional cohorts will be essential to fully assess generalizability and clinical applicability. Second, our interpretability analysis focuses on high-attention patches identified by the ABMIL model and relies heavily on a user-defined hyperparameter governing the number of selected regions, ‘K.’ While this strategy prioritizes biologically salient tissue compartments, future work will explore adaptive selection strategies and whole-granuloma reasoning to reduce parameter sensitivity further. Third, while the LLM-based interpretation provides insights into cellular patterns within high-attention regions, this approach has inherent limitations. The LLM operates as a black-box system, making it difficult to fully understand how it integrates spatial coordinates, cell identities, and expression values to generate its interpretations. Given these constraints and the potential for AI-generated misinterpretations, maintaining pathologist oversight remains essential to validate LLM outputs and ensure biological accuracy. Additionally, due to computational constraints, the LLM analyzes only high-attention patches rather than entire granulomas, which may not capture the complete organization of immune cells or address broader biological phenomena occurring at the whole-granuloma or whole-lung level. Furthermore, the LLM’s reasoning is inherently constrained by the specific set of biomarkers included in the study panel, and the patterns it identifies might not always align with or capture the full spectrum of human-identified biological patterns. This discordance may arise because relevant cellular populations or biological processes that are recognizable through other markers or visual morphological features may not be adequately represented in our current marker panel, and hypothesis-free pattern discovery, potentially limiting the LLM’s ability to detect or interpret certain biologically significant phenomena. For instance, while progressors are known to exhibit large neutrophilic infiltrates, the absence of a neutrophil-specific marker in our panel means that the LLM’s interpretations cannot directly assess this phenomenon, and conclusions are necessarily limited to the cellular populations and markers available in the dataset. Finally, a limitation of this study is the absence of functional markers for spatial localization within granulomas. The current mIF panel was designed to identify and spatially quantify major immune and epithelial cell populations, namely CD4+ T cells, CD8a+ T cells, CD19+ B cells, IBA1+ macrophages, and EpCAM+ epithelial cells, but did not include markers of macrophage polarization states such as M1/M2 indicators, or key inflammatory cytokines such as TNFα and IL-1β. The inclusion of such functional markers would provide additional biological context for interpreting the spatial patterns observed across disease states and strengthen the conclusions drawn from spatial proximity analyses. Future studies incorporating functional markers alongside cell identity markers in expanded mIF panels would offer a more comprehensive characterization of the immune microenvironment within granulomas across the Progressor, Asymptomatic, and Controller phenotypes, and are an important direction for subsequent work.

The study also has limitations related to cohort composition and validation. The 48 mIF specimens represent a retrospectively selected subset of archived samples from previously conducted studies, and therefore potential selection bias cannot be excluded. In addition, the Controller group encompassed a broad range of disease durations (114–418 days post-infection). Although these animals met the previously established phenotypic definition of chronic pulmonary TB, the present study was not designed to determine whether cellular composition and spatial immune organization remain constant across different durations of chronic disease. This temporal heterogeneity may therefore contribute to within-group biological variability. Finally, an independent, blinded mIF cohort was not available for external validation. Although model performance was assessed using five-fold cross-validation, future studies should evaluate the locked framework in independently collected and blinded mIF cohorts.

In summary, this study establishes a foundation for automated, interpretable, and biologically grounded characterization of TB granulomas. Our proposed framework achieves precise delineation of TB granulomas, accurate disease-state classification, and interpretation of complex spatial cellular patterns. The substantial improvement over traditional H&E-based methods highlights the advantage of incorporating cell-type–specific spatial information into computational pathology workflows.

Supporting information

S1 File. Supplementary material.

Contains Supplementary Figure S1 showing the density of immune cell populations per unit granuloma area across TB disease states with 10% boundary shrinkage applied, and Supplementary Figure S2 showing the total numbers of immune cells in granulomas across TB disease states with 10% boundary shrinkage applied.

(DOCX)

pone.0358334.s001.docx (349.1KB, docx)

Acknowledgments

We thank Dr. Sam Telford III and the biocontainment staff at the New England Regional Biosafety Laboratory at Tufts University Cummings School of Veterinary Medicine, North Grafton, MA, USA, for support with biosafety level three facilities. We thank the NEIDL Comparative Pathology Laboratory (NCPL) for their support generating the mIF images. The authors gratefully acknowledge the Ohio Supercomputer Center for providing high-performance computing resources under its contract with The Ohio State University College of Medicine. We acknowledge the use of Claude (Anthropic) for grammatical editing during manuscript preparation; all suggestions were reviewed by the authors to ensure scientific accuracy and integrity.

Data Availability

The data underlying the findings of this study are available at: https://doi.org/10.5281/zenodo.18330801.

Funding Statement

The work was supported through National Institutes of Health (NIH) R01 HL145411 (PI: GB) and R01 CA276301 (PI: MKKN). The instruments utilized for IHC and fluorescent whole-slide scanning were acquired with support from NIH SIG grants (S10OD026983 and S10OD030269). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funder had no additional role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.World Health Organization. Global report on infection prevention and control 2024. World Health Organization; 2024. [Google Scholar]
  • 2.Tavolara TE, Niazi MKK, Ginese M, Piedra-Mora C, Gatti DM, Beamer G, et al. Automatic discovery of clinically interpretable imaging biomarkers for Mycobacterium tuberculosis supersusceptibility using deep learning. EBioMedicine. 2020;62:103094. doi: 10.1016/j.ebiom.2020.103094 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Koyuncu D, Tavolara T, Gatti DM, Gower AC, Ginese ML, Kramnik I, et al. B cells in perivascular and peribronchiolar granuloma-associated lymphoid tissue and B-cell signatures identify asymptomatic Mycobacterium tuberculosis lung infection in Diversity Outbred mice. Infect Immun. 2024;92(7):e0026323. doi: 10.1128/iai.00263-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis. 2011;204 Suppl 4(Suppl 4):S1179-86. doi: 10.1093/infdis/jir451 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76. doi: 10.1183/13993003.01245-2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria? Clin Dev Immunol. 2012;2012:139127. doi: 10.1155/2012/139127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sholeye AR, Williams AR, Loots DT, Tutu van Furth AM, van der Kuip M, Mason S. Tuberculous granuloma: emerging insights from proteomics and metabolomics. Front Neurol. 2022;13:804838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yang H, Bell TA, Churchill GA, Pardo-Manuel de Villena F. On the subspecific origin of the laboratory mouse. Nat gene. 2007;39(9):1100–7. [DOI] [PubMed] [Google Scholar]
  • 9.Yang H, Wang JR, Didion JP, Buus RJ, Bell TA, Welsh CE, et al. Subspecific origin and haplotype diversity in the laboratory mouse. Nat Genet. 2011;43(7):648–55. doi: 10.1038/ng.847 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kurtz SL, Rossi AP, Beamer GL, Gatti DM, Kramnik I, Elkins KL. The diversity outbred mouse population is an improved animal model of vaccination against tuberculosis that reflects heterogeneity of protection. mSphere. 2020;5(2):e00097-20. doi: 10.1128/mSphere.00097-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Churchill GA, Gatti DM, Munger SC, Svenson KL. The diversity outbred mouse population. Mamm Genome. 2012;23(9):713–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rehman Akbar A, Sajjad U, Su Z, Li W, Xing F, Ruiz J, et al. CellEcoNet: decoding the Cellular language of pathology with deep learning for invasive lung adenocarcinoma recurrence prediction. arXiv 2025. Aug:arXiv-2508.
  • 13.Sajjad U, Akbar AR, Su Z, Knight D, Frankel WL, Gurcan MN, et al. Morphology-aware prognostic model for five-year survival prediction in colorectal cancer from H&E whole slide images. arXiv 2025:arXiv:2510.14800. [DOI] [PMC free article] [PubMed]
  • 14.Tavolara TE, Niazi MKK, Gower AC, Ginese M, Beamer G, Gurcan MN. Deep learning predicts gene expression as an intermediate data modality to identify susceptibility patterns in Mycobacterium tuberculosis infected Diversity Outbred mice. EBioMedicine. 2021;67:103388. doi: 10.1016/j.ebiom.2021.103388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hörst F, Rempe M, Heine L, Seibold C, Keyl J, Baldini G, et al. Cellvit: vision transformers for precise cell segmentation and classification. Med Image Anal. 2024;94:103143. [DOI] [PubMed] [Google Scholar]
  • 16.Sajjad U, Khan Niazi K, Beamer G, Gurcan MN. Clinically interpretable imaging biomarker discovery in BCG-vaccinated mycobacterium tuberculosis-infected diversity outbred mice using deep learning. In: Medical Imaging 2025: Digital and Computational Pathology; 2025. pp. 23. 10.1117/12.3047288 [DOI]
  • 17.Su Z, Akbar AR, Sajjad U, Parwani AV, Niazi MK. Streamline pathology foundation model by cross-magnification distillation. arXiv. 2025:arXiv:2509.23097.
  • 18.Akbar AR, Sajjad U, Su Z, Li W, Xing F, Ruiz J, et al. Learning the language of histopathology images reveals prognostic subgroups in invasive lung adenocarcinoma patients. Res Sq. 2026:rs-3.
  • 19.Tavolara TE, Niazi MKK, Beamer G, Gurcan MN. Identifying lung imaging biomarkers of BCG vaccination after infection with Mycobacterium tuberculosis. In: Medical Imaging 2021: Digital Pathology; 2021. p. 7. 10.1117/12.2581945 [DOI]
  • 20.Tavolara TE, Niazi MKK, Ginese M, Piedra-Mora C, Gatti DM, Beamer G, et al. Automatic discovery of clinically interpretable imaging biomarkers for Mycobacterium tuberculosis supersusceptibility using deep learning. EBioMedicine. 2020;62:103094. doi: 10.1016/j.ebiom.2020.103094 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ahmed M, Thirunavukkarasu S, Rosa BA, Thomas KA, Das S, Rangel-Moreno J, et al. Immune correlates of tuberculosis disease and risk translate across species. Sci Transl Med. 2020;12(528):eaay0233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Niazi MKK, Dhulekar N, Schmidt D, Major S, Cooper R, Abeijon C, et al. Lung necrosis and neutrophils reflect common pathways of susceptibility to Mycobacterium tuberculosis in genetically diverse, immune-competent mice. Dis Model Mech. 2015;8(9):1141–53. doi: 10.1242/dmm.020867 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kus P, Gurcan MN, Beamer G. Automatic detection of granuloma necrosis in pulmonary tuberculosis using a two-phase algorithm: 2D-TB. Microorganisms. 2019;7(12):661. doi: 10.3390/microorganisms7120661 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Gatti DM, Tyler AL, Mahoney JM, Churchill GA, Yener B, Koyuncu D, et al. Systems genetics uncover new loci containing functional gene candidates in Mycobacterium tuberculosis-infected Diversity Outbred mice. PLoS Pathog. 2024;20(6):e1011915. doi: 10.1371/journal.ppat.1011915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Koyuncu D, Niazi MKK, Tavolara T, Abeijon C, Ginese ML, Liao Y, et al. CXCL1: a new diagnostic biomarker for human tuberculosis discovered using Diversity Outbred mice. PLoS Pathog. 2021;17(8):e1009773. doi: 10.1371/journal.ppat.1009773 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zhou Z, Rahman SM, Tajbakhsh N, Liang J. “Unet++: A nested u-net architecture for medical image segmentation. In: Deep learning in medical image analysis and multimodal learning for clinical decision support: 4th international workshop, DLMIA 2018, and 8th international workshop, ML-CDS 2018, held in conjunction with MICCAI 2018, Granada, Spain, September 20, 2018, proceedings 4; 2018: Springer, pp. 3–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Stringer C, Wang T, Michaelos M, Pachitariu M. Cellpose: a generalist algorithm for cellular segmentation. Nat Method. 2021;18(1):100–6. [DOI] [PubMed]
  • 28.Dundar MM, Badve S, Raykar VC, Jain RK, Sertel O, Gurca MN. A multiple instance learning approach toward optimal classification of pathology slides. In: 2010 20th International Conference on Pattern Recognition; 2010. pp. 2732–5. 10.1109/icpr.2010.669 [DOI]
  • 29.Dundar MM, Badve S, Bilgin G, Raykar V, Jain R, Sertel O, et al. Computerized classification of intraductal breast lesions using histopathological images. IEEE Trans Biomed Eng. 2011;58(7):1977–84. doi: 10.1109/TBME.2011.2110648 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sajjad U, Rezapour M, Su Z, Tozbikian GH, Gurcan MN, Niazi MKK. NRK-ABMIL: subtle metastatic deposits detection for predicting lymph node metastasis in breast cancer whole-slide images. Cancers (Basel). 2023;15(13):3428. doi: 10.3390/cancers15133428 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ilse M, Tomczak J, Welling M. Attention-based deep multiple instance learning. Int Conf Mach Learn. 2018:2127–36.
  • 32.Shen M, Li Y, Chen L, Yang Q. From mind to machine: the rise of manus ai as a fully autonomous digital agent. arXiv 2025;arXiv:2505.02024.
  • 33.McKeen-Polizzotti L, Henderson KM, Oztan B, Bilgin CC, Yener B, Plopper GE. Quantitative metric profiles capture three-dimensional temporospatial architecture to discriminate cellular functional states. BMC Med Imaging. 2011;11:11. doi: 10.1186/1471-2342-11-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lu MY, Chen B, Williamson DFK, Chen RJ, Zhao M, Chow AK, et al. A multimodal generative AI copilot for human pathology. Nature. 2024;634(8033):466–73. doi: 10.1038/s41586-024-07618-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Afzaal U, Su Z, Sajjad U, Stack T, Lu H, Niu S, et al. HistoChat: instruction-tuning multimodal vision language assistant for colorectal histopathology on limited data. Patterns (N Y). 2025;6(8):101284. doi: 10.1016/j.patter.2025.101284 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Afzaal U, Su Z, Sajjad U, Stack T, Rezapour M, Lu H, et al. Instruction tuning for colorectal histopathology: a multimodal vision-language assistant on human-evaluated data. In: Medical Imaging 2025: Digital and Computational Pathology; 2025. Vol. 13413, pp. 127–34. [DOI] [PMC free article] [PubMed]
  • 37.Sajjad U, Akbar A, Khan H, Frankel W, Gurcan M, Parwani A, et al. 711 an AI virtual agent for prognostic interpretation: translating black-box predictions into clinical insights. Lab Invest. 2026;106(3):104998. doi: 10.1016/j.labinv.2025.104998 [DOI] [Google Scholar]
  • 38.Amirizaniani M, Martin E, Sivachenko M, Mashhadi A, Shah C. Can LLMs reason like humans? Assessing theory of mind reasoning in LLMs for open-ended questions. In: Proceedings of the 33rd ACM International Conference on Information and Knowledge Management, 2024. pp. 34–44. 10.1145/3627673.3679832 [DOI]
  • 39.Li D, Cao S, Griggs T, Liu S, Mo X, Tang E, et al. LLMs can easily learn to reason from demonstrations structure, not content, is what matters! arXiv 2025:arXiv:2502.07374.
  • 40.Ulrichs T, Kaufmann SHE. New insights into the function of granulomas in human tuberculosis. J Pathol. 2006;208(2):261–9. doi: 10.1002/path.1906 [DOI] [PubMed] [Google Scholar]
  • 41.Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat Med. 2016;22(5):531–8. doi: 10.1038/nm.4073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Sawyer AJ, Patrick E, Edwards J, Wilmott JS, Fielder T, Yang Q, et al. Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis. J Exp Med. 2023;220(6):e20221392. doi: 10.1084/jem.20221392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gregg RW, Maiello P, Borish HJ, Coleman MT, Reed DS, White AG, et al. Spatial and temporal evolution of lung granulomas in a cynomolgus macaque model of Mycobacterium tuberculosis infection. Radiol Infect Dis. 2018;5(3):110–7. doi: 10.1016/j.jrid.2018.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun. 2009;77(10):4631–42. doi: 10.1128/iai.00592-09 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Selvakumar Subbian

15 May 2026

Dear Dr. Sajjad,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:  Although the premise of this article seems innovative, a major and significant flaw in this article is the over-emphasis of the mouse lung granulomas as a prototype for human TB disease states.  This is fundamentally incorrect and leads to misconception of "disease state" defined in human TB.  It is unclear as what exactly the mouse "disease state" that correlate with the human counterpart in this study? As the authors may aware, standard mouse granulomas are strikingly different from the highly complex, heterogenous and evolved human granulomas. There is no equivalent of necrotizing, caseating, liquefied and cavitary lesions in mouse lungs infected with TB; however, these were hallmarks in human TB. For example, cavitary granulomas are associated with active TB, which is a disease state. Thus, assigning a "disease state" with mostly a cellular aggregate-type granulomas that doesn't have the crucial "maturity" of granulomas in the mice model is incorrect.  At this point, I suggest the authors to revise the title and the content of the article to align with what is factual in the mice model granulomas. For example, the authors may focus their tone towards how to improvise the spatial immunoprofiling of mouse lung granulomas, without linking any "disease state", since there is no true correlate of "disease state" in mice that represent the spectrum of outcomes in humans.  Rather the focus should be on how to gain more insight into the heterogeneous lung granulomas in the DO mice using DL-based spatial immunoprofiling. If the authors would like to challenge this view, then they should provide evidence of "disease state" in their mouse model, such as sputum positivity, x-ray scores, fever, weight loss etc., these are some of the standard diagnostic measures to evaluate the disease state in human TB.

==============================

Please submit your revised manuscript by Jun 29 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. Thank you for stating in your Funding Statement:

[The work was supported through a National Institutes of Health (NIH) R01 HL145411 (PI: Beamer), R01 CA276301 (PIs: Niazi, Chen). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.].

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

4. Please remove any funding-related text from the manuscript. Please note that funding information should not appear in any section or other areas of your manuscript. We will publish the funding statement that is present in the Financial Disclosure section of the online submission form.

5. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: In this review, the authors have devised artificial intelligence and machine learning techniques to analyze Tuberculous granulomas for better understanding of disease progression and prediction. The study highlights the significant bottlenecks in understanding Tuberculosis. However, I have following concerns regarding the manuscript,

1. The authors have not included any functional markers (e.g., M1/M2 polarization, TNFα, IL1β) for spatial localization and their significance? This is very important for coming to any conclusion.

2. Given the subjectivity in granuloma boundary definition, how do the authors ensure annotation consistency across samples?

3. Did the authors quantitatively compare predicted vs. true granuloma morphology (e.g., size, shape descriptors.

4. How does segmentation quality impact downstream biological interpretation or feature extraction.

5. The classification labels are defined by survival: Progressor (<60 days) vs. Controller (>60 days). Is this threshold biologically justified or empirically chosen? Also, how stable are these labels across cohorts? Could survival-based labeling introduce bias unrelated to granuloma morphology?

6. Please clarify how distances were computed from pixel-to-micron.

7. How were bronchiolar epithelial cells defined? Based on EpCAM positivity alone? Were airway structures (bronchioles) explicitly segmented or annotated? EpCAM+ cells may include non-bronchiolar epithelial cells unless spatially constrained.

8. Why would closer B-cell proximity to bronchiolar epithelium associated with asymptomatic infection?

9. Were analyses stratified by: Granuloma size? Necrotic vs. non-necrotic lesions? Spatial organization can vary dramatically with granuloma stage.

Reviewer #2: Authors investigated the spatial distribution of lung granulomas in different clinical stages of tuberculosis disease using a mouse model. The authors developed a novel automated model for granuloma segmentation in lung tissues. The study demonstrates distinct spatial distributions of CD4+ and CD8a+ positive cells during the asymptomatic stage of disease. In addition, the LLM model decoded complex cellular patterns within granulomas, including balanced immune responses in asymptomatic mice, dysfunctional responses with low cellularity in acute TB, and increased immune cell accumulation during chronic disease. Overall, the findings are interesting and contribute valuable insights into the immunopathology of tuberculosis.

Major Comments:

1. The authors performed multiplex immunofluorescence imaging of lung sections. Did the authors use sequential staining on the same tissue sections after stripping the previous antibodies/signals? This is not clearly described in the Methods section.

2. The study used lung sections from DO mice infected with M. tuberculosis. Which M. tuberculosis strain was used for infection? What inoculum size was used in this study?

3. Did the authors quantify the bacterial burden in the lungs of the different disease groups, such as progressors, asymptomatic mice, and controllers? Was there any correlation between the spatial distribution of immune cells and the bacterial load at different stages of disease progression? Additionally, what time points were selected for analysis in this study? These details are currently missing.

4. How did the authors define the asymptomatic stage of infection in the mouse model? Figure 1B shows lung scan images with granuloma segmentation during the asymptomatic stage; however, multiple granulomas appear to be present, similar to those observed in acute disease. Please clarify this point.

5. The authors used the IF-UNet++ segmentation model for image analysis. What are the advantages of this model compared with other segmentation algorithms, such as Cellpose, which has been used in similar studies (Kumar et al., 2024)?

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes: Ranjeet Kumar

Reviewer #2: Yes: Afsal Kolloli

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Sep 25;21(9):e0358334. doi: 10.1371/journal.pone.0358334.r002

Author response to Decision Letter 1


7 Jul 2026

Reviewer #1: In this review, the authors have devised artificial intelligence and machine learning techniques to analyze Tuberculous granulomas for better understanding of disease progression and prediction. The study highlights the significant bottlenecks in understanding Tuberculosis. However, I have following concerns regarding the manuscript,

1. The authors have not included any functional markers (e.g., M1/M2 polarization, TNFα, IL1β) for spatial localization and their significance? This is very important for coming to any conclusion.

We thank the reviewer for this important and valid observation. We acknowledge that the absence of functional markers such as M1/M2 polarization indicators, TNFα, and IL-1β for spatial localization is a limitation of the current study, and we have added this to the limitations section of the Discussion accordingly. The primary aim of this study was to develop and validate an automated computational framework for granuloma segmentation, disease-state classification, and spatial quantification of immune cell populations from mIF images, rather than to provide a comprehensive functional characterization of immune responses across disease states. The functional immune and inflammatory responses, bacterial control capacities, and molecular signatures of the Progressor, Asymptomatic, and Controller phenotypes have been extensively studied in our prior work and by others, using protein detection methods, gene expression profiling, and pathway analysis. Specifically, lung cytokines and chemokines including TNFα, IFN-γ, IL-10, CXCL1, CXCL2, CXCL5, MMP8, S100A8, and VEGF have been quantified and analyzed across disease states in our previously published studies [1-6]. The immune and inflammatory correlates of these disease phenotypes have also been validated by independent groups [7, 8].

The current study builds on this established functional foundation by adding a spatial dimension, quantifying where immune cells are located within granulomas and how those spatial relationships differ across disease states. The inclusion of functional markers for spatial localization in future mIF panels is an important direction that we fully agree with and acknowledge as a priority for subsequent work.

2. Given the subjectivity in granuloma boundary definition, how do the authors ensure annotation consistency across samples?

We thank the reviewer for this insightful question. The authors ensured annotation consistency by grounding the entire segmentation pipeline in expert pathological knowledge. Granuloma boundary annotations were delineated by a board-certified pathologist, providing biologically accurate and consistent ground truth segmentation masks for model training. Importantly, deep learning segmentation models learn by identifying recurring patterns in training data, meaning that inconsistent or contradictory annotations across samples would prevent the model from learning a coherent decision boundary, ultimately resulting in poor performance on unseen data. The IF-UNet++ model was then trained on these expert-defined granuloma annotations and quantitatively evaluated, achieving an IoU of 90.57% on the test set, demonstrating that the model successfully learned to replicate pathologist-level accuracy across diverse disease states and tissue morphologies. The fact that IF-UNet++ achieves high IoU on samples never seen during training is therefore not only a measure of model accuracy but also indirect quantitative evidence that the underlying annotations were consistent and reproducible across the dataset. Beyond quantitative evaluation, the segmentation results were mapped back to the original mIF images and qualitatively reviewed by a board-certified pathologist, who confirmed that the predicted granuloma boundaries were spatially concordant with true granulomatous structures across all disease phenotypes. Taken together, the expert-guided annotation, strong quantitative performance, and qualitative pathologist validation form a coherent and mutually reinforcing validation strategy that collectively addresses the inherent subjectivity in granuloma boundary definition. We have expanded this into section 3.1.

3. Did the authors quantitatively compare predicted vs. true granuloma morphology (e.g., size, shape descriptors.

We performed the quantitative comparison of predicted versus true granuloma morphology using the Intersection over Union (IoU) metric, which serves as a comprehensive surrogate for all aspects of granuloma morphological accuracy, including size, shape, spatial extent, and boundary fidelity.

IoU is computed by dividing the area of overlap between the predicted segmentation mask and the ground truth mask by the area of their union. If the predicted boundary is too large or too small, the size mismatch directly penalizes the score. If the shape is incorrect, the misaligned boundaries reduce the shared region and lower the IoU. If the spatial location is off, the same penalty applies. In this way, IoU implicitly encodes agreement in size, shape, location, and boundary fidelity all within a single unified metric, making it a comprehensive surrogate for granuloma morphological accuracy without requiring each descriptor to be reported separately.

Our IF-UNet++ model achieved an IoU of 93.22% on the training set and 90.57% on the test set, demonstrating strong spatial and morphological agreement with the pathologist-defined ground truth across diverse disease states and tissue morphologies. We therefore believe that the high IoU scores reported in our study provide sufficient evidence of accurate granuloma geometry capture, and that these results are adequate for supporting the reliability of our downstream spatial and disease-state analyses. We have further clarified it in section 3.1.

4. How does segmentation quality impact downstream biological interpretation or feature extraction.

We thank the reviewer for highlighting the importance of segmentation quality with respect to downstream biological interpretation and feature extraction. To directly address this question, we introduced controlled perturbation by deliberately shrinking the granuloma boundary by 10% of its area and recomputed downstream cellular metrics, including immune cell density per unit granuloma area and total immune cell counts across all cell types (Supplementary Figure S1, S2).

Our findings demonstrate that although the absolute value of cell counts and densities change because of the boundary perturbation, the overall biological trends across the three disease groups, namely Progressor, Asymptomatic, and Controller, remain consistent with our original results. This indicates that our downstream biological interpretations are robust to minor segmentation inaccuracies and are not artifacts of precise boundary placement. The biological signatures we report, such as higher CD4+ and CD8a+ T cell densities in Asymptomatic mice and elevated total cell counts in Controllers, are preserved under this perturbation, supporting the stability and reliability of our conclusions.

We have added the corresponding plots as Supplementary Figures S1 and S2, showing density of immune cell populations per unit granuloma area and total immune cell numbers respectively, both computed under the 10% boundary shrinkage condition, for all five cell types across the three disease states. These supplementary results collectively demonstrate that our framework produces conclusions that are resilient to small variations in segmentation quality.

A. CD4 B. CD8a

C. CD19 D. IBA1

E. EPCAM

Supplementary Figure S1. Density of immune cell populations per unit granuloma area across TB disease states (10% boundary shrinkage applied). Box plots show density of cells, reported as density per unit granuloma area for (A) CD4+ T cells, (B) CD8a+ T cells, (C) CD19+ B cells, (D) IBA1+ macrophages, and (E) EpCAM+ epithelial cells across three disease groups: Progressor, Asymptomatic, and Controller. Each dot represents one granuloma; box plots show median, interquartile range, and whiskers extending to 1.5× IQR.

A. CD4 B. CD8a

C. CD19 D. IBA1

E. EPCAM

Supplementary Figure S2. Total numbers of immune cells in granulomas across TB disease states (10% boundary shrinkage applied). Box plots showing cell abundance for (A) CD4+ T cells, (B) CD8a+ T cells, (C) CD19+ B cells, (D) IBA1+ macrophages, and (E) EpCAM+ epithelial cells across three disease groups: Progressor, Asymptomatic TB, and Controller. Each dot (4A-4E) represents one granuloma; box plots show median, interquartile range, and whiskers extending to 1.5× IQR.

5. The classification labels are defined by survival: Progressor (<60 days) vs. Controller (>60 days). Is this threshold biologically justified or empirically chosen? Also, how stable are these labels across cohorts? Could survival-based labeling introduce bias unrelated to granuloma morphology?

The 60-day survival threshold is biologically justified and empirically well-supported across our cohorts. As described in our previously published work [5], across nearly 1,000 total DO mice spanning cohorts of approximately 125 mice each, 25–30% consistently develop pulmonary TB morbidity requiring euthanasia prior to day 60, with a peak morbidity wave occurring between days 25–35 post-infection. The remaining 70–75% are asymptomatic through this 60-day window and many remain so substantially beyond that, up to nearly 2 years. This survival pattern across independent cohorts demonstrates that the 60-day threshold captures a real and stable biological boundary between acute disease susceptibility and bacterial control, rather than an arbitrary cutoff.

We acknowledge that survival-based labeling could theoretically introduce bias if mice developed morbidity due to non-TB disease. This was minimized by examining all mice through multiple approaches to confirm that morbidity was related to pulmonary TB and not to other co-morbidities. Mice with clear co-morbidities were excluded and are not included in any analyses presented here. The detailed methods used to ensure that morbidity was attributable to TB rather than other disease are described in the Quantification of TB-related Traits (Phenotyping) section of our previously published work [5].

6. Please clarify how distances were computed from pixel-to-micron.

We appreciate the reviewer raising this point. Our WSIs have a spatial resolution of 0.5 microns per pixel (mpp), meaning each pixel corresponds to a physical length of 0.5 µm in tissue space. To ensure biologically meaningful spatial analysis, all pixel-based distance measurements were converted to physical units using this linear scaling factor. Specifically, to identify cell populations within a 75 µm radius, we converted the radius from microns to pixels using the formula: RadiusInPixels = RadiusInMicrons / mpp = 75 / 0.5 = 150 pixels. This conversion was applied uniformly across all WSIs to maintain consistency in defining spatial neighborhoods. The resulting 150-pixel radius was then used to query and count cell populations within that spatial boundary for each cell of interest. This approach ensures that our proximity-based analysis reflects true physical distances in tissue, independent of any pixel-resolution variability across imaging sessions. We have clarified it in the manuscript section 3.5.

7. How were bronchiolar epithelial cells defined? Based on EpCAM positivity alone? Were airway structures (bronchioles) explicitly segmented or annotated? EpCAM+ cells may include non-bronchiolar epithelial cells unless spatially constrained.

EpCAM positive cells were confirmed to be bronchiolar epithelial cells based on the anatomic structure highlighted by board certified pathologists. We have clarified it in section 3.2.

8. Why would closer B-cell proximity to bronchiolar epithelium associated with asymptomatic infection?

This is a good question that we did not address directly here but could be an association or a mechanism. A plausible hypothesis is that B-cells in that region are differentiating into plasma cells that may secrete IgA into the airways or IgG into the blood stream that may help the host control infection in the lungs or limit dissemination.

9. Were analyses stratified by: Granuloma size? Necrotic vs. non-necrotic lesions? Spatial organization can vary dramatically with granuloma stage.

Analyses were stratified by host disease state. We agree that stratification by other means is a good idea and spatial organization can vary by granuloma stage. These types of questions may be better answered by separate experiments using inbred strains of mice at pre-defined time points.

Reviewer #2: Authors investigated the spatial distribution of lung granulomas in different clinical stages of tuberculosis disease using a mouse model. The authors developed a novel automated model for granuloma segmentation in lung tissues. The study demonstrates distinct spatial distributions of CD4+ and CD8a+ positive cells during the asymptomatic stage of disease. In addition, the LLM model decoded complex cellular patterns within granulomas, including balanced immune responses in asymptomatic mice, dysfunctional responses with low cellularity in acute TB, and increased immune cell accumulation during chronic disease. Overall, the findings are interesting and contribute valuable insights into the immunopathology of tuberculosis.

Major Comments:

1. The authors performed multiplex immunofluorescence imaging of lung sections. Did the authors use sequential staining on the same tissue sections after stripping the previous antibodies/signals? This is not clearly described in the Methods section.

We use tyramide signaling amplification for our multiplex immunofluorescence images. In each staining cycle, a primary-secondary antibody complex was applied, followed by covalent deposition of the fluorophore onto the tissue via tyramide signal amplification. The primary-secondary antibody complex was then stripped iteratively using heat and a low-pH citrate buffer, while the covalently bound fluorophore signal was retained in the tissue. This cycle was repeated sequentially for each target marker (CD4+, CD8a+, CD19+, EpCAM+, and IBA1+) on the same tissue section, enabling simultaneous visualization of all five immune and epithelial cell populations without cross-reactivity between staining rounds. We have clarified the staining protocol in Section 2.2.

2. The study used lung sections from DO mice infected with M. tuberculosis. Which M. tuberculosis strain was used for infection? What inoculum size was used in this study?

DO mice were infected with the M. tb Erdman strain with a retained lung dose of 25–100 colony forming units (CFU), as described in our previously published work [5]. The range of euthanasia day and lung bacterial burden for each disease group are now provided in Table 1.

3. Did the authors quantify the bacterial burden in the lungs of the different disease groups, such as progressors, asymptomatic mice, and controllers? Was there any correlation between the spatial distribution of immune cells and the bacterial load at different stages of disease progression? Additionally, what time points were selected for analysis in this study? These details are currently missing.

We performed a correlation analysis between spatial immune cell distribution and bacterial load, and present it in the newly added Section 3.7 and Figure 8. Spearman correlation coefficients were computed per disease group between the log mean distance of each immune cell population (CD4+ T cells, CD8a+ T cells, CD19+ B cells, IBA1+ macrophages, and EpCAM+ epithelial cells) and M.tb burden for each mouse. The per-group Spearman correlation coefficients (ρ) and associated p-values are provided in each panel of Figure 8. The results indicate that spatial immune organization, particularly T cell proximity, shows disease-state-specific associations with bacterial burden, with Asymptomatic mice displaying distinct spatial-bacterial relationships compared to Progressors and Controllers.

Regarding time points, tissue sections were collected at the time of euthanasia, which varied by disease outcome: Progressors were euthanized within 60 days of infection reflecting acute pulmonary TB, Controllers were euthanized after 60 days reflecting chronic pulmonary TB, with the longest surviving Controller reaching 418 days post-infection, and Asymptomatic mice showed no clinical signs of disease throughout the observation period. These details are described in Section 2.2, and Table 1.

4. How did the authors define the asymptomatic stage of infection in the mouse model? Figure 1B shows lung scan images with granuloma segmentation during the asymptomatic stage; however, multiple granulomas appear to be present, similar to those observed in acute disease. Please clarify this point.

We thank the reviewer for this important clarifying question. Asymptomatic mice in this study are defined by the absence of outward clinical signs of disease: they remain infected, develop granulomas, and gain weight to the same degree as non-infected controls throughout the observation period, as described in detail in our previously published work [6].

Regarding the appearance of granulomas in Figure 1B, granulomas in Asymptomatic mice may appear morphologically similar in size and shape to those in Progressors on mIF imaging. This is expected and does not reflect a classification error. The key distinguishing pathological feature of Progressor granulomas is neutrophilic infiltration and necrosis, which is not visible by immunofluorescence imaging but is clearly demonstrable by hematoxylin and eosin staining, as we have described previously [1-6]. We have clarified that in the discussion section of the manuscript.

5. The authors used the IF-UNet++ segmentation model for image analysis. What are the advantages of this model compared with other segmentation algorithms, such as Cellpose, which has been used in similar studies (Kumar et al., 2024)?

Cellpose and similar cell segmentation algorithms are designed to delineate individual cells, identifying and separating each cell's boundary in an image. In this study, the biological task is fundamentally different. The goal is to segment granulomas, which are entire multicellular structures composed of clusters of immune cells (T cells, B cells, macrophages, and others) organized around M.tb-infected tissue. These are not single cells but complex, heterogeneous tissue-level structures that can span large regions of a WSIs. Using a cell-segmentation tool like Cellpose for granuloma delineation would be a category mismatch: it would produce tens of thousands of individual cell outlines rather than a single boundary around the granuloma as a functional immunological unit.

The IF-UNet++ model was specifically designed and optimized for this granuloma-level task. It is an immunofluorescence-adapted UNet++ architecture that processes multiple immunofluorescence channels simultaneously (CD4+, CD8a+, CD19+, EpCAM+, IBA1+), leveraging all available marker information to accurately identify granuloma boundaries in complex multiplex images, whereas standard segmentation tools like Cellpose are typically optimized for brightfield or single-channel fluorescence microscopy. Furthermore, the model was trained and validated on gigapixel-scale WSIs, achieving an IoU of 93.22% on the training set and 90.57% on an independent test set, demonstrating robust generalization that would be unattainable by repurposing a cell-segmentation model. Finally, because IF-UNet++ precisely delineates the granuloma as a biological unit, all subsequent spatial analyses including T cell-macrophage proximity, B cell-epithelial cell distances, and immune cell densities are anchored to biologically meaningful boundaries, which a cell-level segmentation tool cannot provide. We have clarified that in section 2.4.1, 3.1.

References:

[1] M. K. Niazi et al., "Lung necrosis and neutrophils reflect common pathways of susceptibility to Mycobacterium tuberculosis in genetically diverse, immune-competent mice," Disease models & mechanisms, vol. 8, no. 9, pp. 1141-1153, 2015.

[2] T. E. Tavolara et al., "Automatic discovery of clinically interpretable imaging biomarkers for Mycobacterium tuberculosis supersusceptibility using deep learning," EBioMedicine, vol. 62, 2020.

[3] T. E. Tavolara, M. Niazi, A. C. Gower, M. Ginese, G. Beamer, and M. N. Gurcan, "Deep learning predicts gene expression as an intermediate data modality to identify susceptibility patterns in Mycobacterium tuberculosis infected Diversity Outbred mice," EBioMedicine, vol. 67, 2021.

[4] D. Koyuncu et al., "CXCL1: A new diagnostic biomarker for human tuberculosis discovered using Diversity Outbred mice," PLoS Pathogens, vol. 17, no. 8, p. e1009773, 2021.

[5] D. M. Gatti et al., "Systems genetics uncover new loci containing functional gene candidates in Mycobacterium tuberculosis-infected Diversity Outbred mice," PLoS Pathogens, vol. 20, no. 6, p. e1011915, 2024.

[6] D. Koyuncu et al., "B cells in perivascular and peribronchiolar granuloma-associated lymphoid tissue and B-cell signatures identify asymptomatic Mycobacterium tuberculosis lung infection in Diversity Outbred mice," Infection and immunity, vol. 92, no. 7, pp. e00263-23, 2024.

[7] M. Ahmed et al., "Immune correlates of tuberculosis disease and risk translate across species," Science translational medicine, vol. 12, no. 528, p. eaay0233, 2020.

[8] R. Gopal et al., "S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis," American journal of respiratory and critical care medicine, vol. 188, no. 9, pp. 1137-1146, 2013.

Attachment

Submitted filename: resp_to_editor_and_reviewers.docx

pone.0358334.s003.docx (372.3KB, docx)

Decision Letter 1

Selvakumar Subbian

10 Aug 2026

Dear Dr. Sajjad,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

1). Change/Expand the title for section 2.4. This is confusing with the title of Main Section-2.

2). In Section 2.2. Clarify if the 48mIF lug tissue sections are from 48 animals?.  How are these animals selected within their respective cohort. i.e., Did the controllers at 61 days have same tissue pathology and/or cellular distribution as that at 418 days?.  Explain why these extremes were included in data analysis, despite their inherent heterogeneity? .  There’s a discrepency in information between text in Section 2.2 and Table-1. Controllers were euthanized at an average of 255 days (not 60 days as put in the text). Same with progressors and asymptomatic animals. How long are the asymptomatic animals monitored? Make the statements very precise and consistent.  In the “limitations of the study” section of discussion, add the skewed sample selection from prior studies as a weakness. Also, did you use “blinded mIF sections” to independently validate the performance of your DL/LLM-based system? If not, add that as a limitation.

3). In Figure-8, add the unit for lung Mtb burden in the X-axis.

4). The IACUC (animal) and IBC (Mtb) protocols were approved by Tuft University; however, no author or acknowledgment has been provided. This is an important Ethical component; therefore, clarify this and provide clear details.

5). Just be cautious about the claim that “this is the first study to combine mIF, attention-based MIL, and LLM-driven interpretation to distinguish TB disease states at the level of the granuloma in a genetically diverse animal model” in the introduction. I suggest modifying this statement.

Take this opportunity to fully-revise the manuscript for clarity, readability and tyops.

==============================

Please submit your revised manuscript by Sep 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes: Ranjeet Kumar

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Sep 25;21(9):e0358334. doi: 10.1371/journal.pone.0358334.r004

Author response to Decision Letter 2


26 Aug 2026

Dear Editor,

We sincerely thank you for your careful evaluation of our manuscript and for the constructive comments provided during this revision. In response, we have revised the manuscript to clarify the composition, selection, and timing of the Diversity Outbred mouse cohort; explicitly acknowledge cohort heterogeneity, retrospective sample selection, and the lack of an independent blinded validation cohort; clarify the ethical approvals and provenance of the archived specimens; add the appropriate units to Figure 8; and moderate the novelty-related language. We have also carefully reviewed the manuscript throughout to improve clarity, consistency, readability, and grammatical accuracy.

Detailed responses to the Reviewers are below.

Sincerely,

Usama Sajjad, on behalf of the authors

==============================

ACADEMIC EDITOR: The authors must address the following concerns directly on the manuscript,

1). Change/Expand the title for section 2.4. This is confusing with the title of Main Section-2.

We thank the reviewer for this helpful suggestion. In response to the comment, we have revised the title of Section 2.4 to more clearly distinguish it from the main Materials and Methods section and to better reflect the content of the subsection. The revised title is: “Computational Framework for Granuloma Segmentation, Disease-State Classification, and Spatial Interpretation.”

2). In Section 2.2. Clarify if the 48mIF lug tissue sections are from 48 animals?. How are these animals selected within their respective cohort. i.e., Did the controllers at 61 days have same tissue pathology and/or cellular distribution as that at 418 days?. Explain why these extremes were included in data analysis, despite their inherent heterogeneity? . There’s a discrepency in information between text in Section 2.2 and Table-1. Controllers were euthanized at an average of 255 days (not 60 days as put in the text). Same with progressors and asymptomatic animals. How long are the asymptomatic animals monitored? Make the statements very precise and consistent. In the “limitations of the study” section of discussion, add the skewed sample selection from prior studies as a weakness. Also, did you use “blinded mIF sections” to independently validate the performance of your DL/LLM-based system? If not, add that as a limitation.

Thank you for this detailed and important comment. We have revised Section 2.2 to more precisely describe the composition, disease-state definitions, and timing of sample collection in the study cohort. First, we clarify that the 48 mIF lung tissue sections analyzed in this study were obtained from 48 individual DO mice, with one lung tissue section representing each animal (15 Progressors, 17 Asymptomatic mice, and 16 Controllers). Samples for mIF analysis were selected to capture the full range of bacterial burden and survival outcomes within each disease class while maintaining relatively balanced groups for downstream analysis.

We also clarify that the previously stated 60-day time point represents the established phenotypic threshold used to distinguish Progressors from Controllers, rather than the average euthanasia time of either group. Specifically, in the mIF cohort analyzed here, Progressors were euthanized between 22 and 51 days post-infection (mean = 27.05 days), whereas Controllers were euthanized between 114 and 418 days post-infection (mean = 255 days). Asymptomatic mice were euthanized at predetermined time points between 48 and 50 days post-infection (mean = 49 days) and remained clinically asymptomatic during this observation period. These definitions are consistent with the previously established disease-state criteria in which Progressors develop TB-related morbidity before 60 days, Controllers develop chronic pulmonary TB after surviving beyond 60 days, and Asymptomatic animals remain clinically healthy until their predetermined euthanasia time point. We have revised the text to make these distinctions explicit and consistent with Table 1.

Regarding the broad survival duration among Controllers, these animals were grouped according to their previously established chronic pulmonary TB phenotype rather than according to a fixed post-infection collection time. We agree, however, that the wide range in disease duration may introduce biological heterogeneity within the Controller group. The present study was not designed to determine whether cellular composition or spatial organization remains unchanged across different durations of chronic disease; therefore, we have avoided making such an assumption and now explicitly acknowledge this temporal heterogeneity as a limitation.

The specimens used for mIF represented a retrospectively selected subset of archived samples from the previously characterized cohorts. Because the study used an archived subset rather than a prospectively selected cohort, we have also acknowledged the possibility of selection bias in the Discussion.

Finally, an entirely independent, blinded set of mIF sections was not available for validation of the present framework. Model performance was evaluated using five-fold cross-validation with held-out test samples within the available cohort. We agree that evaluation using an independently collected and blinded mIF cohort would provide a stronger assessment of generalizability, and we have added this point to the limitations of the study.

3). In Figure-8, add the unit for lung Mtb burden in the X-axis.

We thank the reviewer for this helpful suggestion. In response to the reviewer’s comment, we carefully reviewed all figures to ensure that the appropriate units are clearly indicated wherever applicable. In particular, for Figure 8, the unit for lung M. tb burden has now been added to improve clarity and consistency.

A B

C D

E

Figure 8. Correlation between spatial distribution of immune cells and M.tb burden across disease states. (A). Log mean distance for CD4+ T cells (B). CD8a+ T cells, (C). CD19+ B cells, (D). IBA1+ macrophages, and (E). EPCAM+ epithelial cells plotted against M.tb burden for each mouse. Each point represents one mouse, colored by disease group: Asymptomatic (blue), Controllers (green), and Progressors (red). Per-group Spearman correlation coefficients (ρ) and associated p-values are shown in each panel legend.

4). The IACUC (animal) and IBC (Mtb) protocols were approved by Tuft University; however, no author or acknowledgment has been provided. This is an important Ethical component; therefore, clarify this and provide clear details.

Thank you for highlighting this important ethical consideration. We apologize that the relationship between the archived samples and the Tufts University-approved animal studies was not sufficiently clear. The lung tissue samples analyzed in the present study were generated during previously conducted M. tb infection experiments at Tufts University. These experiments were performed under Tufts University IACUC protocols G2012-53, G2015-33, G2018-33, and G2020-121 and IBC registrations GRIA04, GRIA10, GRIA17, and 2020-G61. We have revised the Ethics Statement to explicitly clarify the provenance of these archived specimens and their relationship to the approved protocols. We also note that the Tufts University biocontainment personnel and facilities involved in these studies are acknowledged in the manuscript.

5). Just be cautious about the claim that “this is the first study to combine mIF, attention-based MIL, and LLM-driven interpretation to distinguish TB disease states at the level of the granuloma in a genetically diverse animal model” in the introduction. I suggest modifying this statement.

We thank the reviewer for the great suggestion. In response to the review comments, we have softened the tone of our language and modified the highlighted claim to “Overall, this study integrates mIF imaging, attention-based MIL, and LLM-driven interpretation to characterize granuloma-level cellular and spatial patterns associated with distinct TB disease states in a genetically diverse animal model.”

Take this opportunity to fully-revise the manuscript for clarity, readability and tyops.

==============================

Please submit your revised manuscript by Sep 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ranjeet Kumar

Reviewer #2: No

________________________________________

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

________________________________________

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Remove my information/details). Please contact the publication office if you have any questions.

Decision Letter 2

Selvakumar Subbian

31 Aug 2026

Deep Learning-Based Spatial Immunoprofiling of Multiplex Immunofluorescence Images Distinguishes Tuberculosis Disease States in Diversity Outbred Mice

PONE-D-26-15268R2

Dear Dr. Sajjad,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Selvakumar Subbian, Ph.D.

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Selvakumar Subbian

PONE-D-26-15268R2

PLOS One

Dear Dr. Sajjad,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS One and supporting open access.

Kind regards,

PLOS One Editorial Office Staff

on behalf of

Dr. Selvakumar Subbian

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Supplementary material.

    Contains Supplementary Figure S1 showing the density of immune cell populations per unit granuloma area across TB disease states with 10% boundary shrinkage applied, and Supplementary Figure S2 showing the total numbers of immune cells in granulomas across TB disease states with 10% boundary shrinkage applied.

    (DOCX)

    pone.0358334.s001.docx (349.1KB, docx)
    Attachment

    Submitted filename: resp_to_editor_and_reviewers.docx

    pone.0358334.s003.docx (372.3KB, docx)

    Data Availability Statement

    The data underlying the findings of this study are available at: https://doi.org/10.5281/zenodo.18330801.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES